File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/00001703-200206000-00013
- Scopus: eid_2-s2.0-0036262524
- PMID: 12032390
- WOS: WOS:000175899000013
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Mifepristone: Contraceptive and non-contraceptive uses
Title | Mifepristone: Contraceptive and non-contraceptive uses |
---|---|
Authors | |
Issue Date | 2002 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.co-obgyn.com |
Citation | Current Opinion In Obstetrics And Gynecology, 2002, v. 14 n. 3, p. 325-330 How to Cite? |
Abstract | Mifepristone is an orally active progesterone antagonist. It can be used for both contraceptive and non-contraceptive clinical indications. It is a very effective drug for emergency contraception with a low incidence of side effects. There is a potential for mifepristone to be used as a once-a-month pill. There is a need, however, for a simple, inexpensive and accurate method to identify the luteinizing hormone surge before this method can be used in clinical practice. The daily administration of mifepristone offers promise as an effective method of contraception but more studies need to be done. The combination of mifepristone with a prostaglandin analogue is a well-established method for termination of pregnancy of up to 9 weeks. Recent data suggest that this combination may also be used up to 9-13 weeks of pregnancy. Although mifepristone is effective in dilating the cervix before vacuum aspiration, misoprostol is probably the drug of choice in most situations. In the second trimester, mifepristone is effective in shortening the abortion process induced by prostaglandin analogues. The combination of mifepristone and prostaglandin also offers a medical method for management of miscarriages. Mifepristone has been used for a number of other indications, but further studies are needed before such treatment can be recommended. © 2002 Lippincott Williams & Wilkins. |
Persistent Identifier | http://hdl.handle.net/10722/87225 |
ISSN | 2023 Impact Factor: 2.2 2023 SCImago Journal Rankings: 0.653 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pak, CH | en_HK |
dc.contributor.author | Ng, EHY | en_HK |
dc.contributor.author | Oi, ST | en_HK |
dc.date.accessioned | 2010-09-06T09:26:57Z | - |
dc.date.available | 2010-09-06T09:26:57Z | - |
dc.date.issued | 2002 | en_HK |
dc.identifier.citation | Current Opinion In Obstetrics And Gynecology, 2002, v. 14 n. 3, p. 325-330 | en_HK |
dc.identifier.issn | 1040-872X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/87225 | - |
dc.description.abstract | Mifepristone is an orally active progesterone antagonist. It can be used for both contraceptive and non-contraceptive clinical indications. It is a very effective drug for emergency contraception with a low incidence of side effects. There is a potential for mifepristone to be used as a once-a-month pill. There is a need, however, for a simple, inexpensive and accurate method to identify the luteinizing hormone surge before this method can be used in clinical practice. The daily administration of mifepristone offers promise as an effective method of contraception but more studies need to be done. The combination of mifepristone with a prostaglandin analogue is a well-established method for termination of pregnancy of up to 9 weeks. Recent data suggest that this combination may also be used up to 9-13 weeks of pregnancy. Although mifepristone is effective in dilating the cervix before vacuum aspiration, misoprostol is probably the drug of choice in most situations. In the second trimester, mifepristone is effective in shortening the abortion process induced by prostaglandin analogues. The combination of mifepristone and prostaglandin also offers a medical method for management of miscarriages. Mifepristone has been used for a number of other indications, but further studies are needed before such treatment can be recommended. © 2002 Lippincott Williams & Wilkins. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.co-obgyn.com | en_HK |
dc.relation.ispartof | Current Opinion in Obstetrics and Gynecology | en_HK |
dc.rights | Current Opinion in Obstetrics & Gynecology. Copyright © Lippincott Williams & Wilkins. | en_HK |
dc.title | Mifepristone: Contraceptive and non-contraceptive uses | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1040-872X&volume=14&spage=325&epage=330&date=2002&atitle=Mifepristone:+contraceptive+and+non-contraceptive+uses | en_HK |
dc.identifier.email | Pak, CH:pcho@hku.hk | en_HK |
dc.identifier.email | Ng, EHY:nghye@hkucc.hku.hk | en_HK |
dc.identifier.authority | Pak, CH=rp00325 | en_HK |
dc.identifier.authority | Ng, EHY=rp00426 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1097/00001703-200206000-00013 | en_HK |
dc.identifier.pmid | 12032390 | - |
dc.identifier.scopus | eid_2-s2.0-0036262524 | en_HK |
dc.identifier.hkuros | 66987 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0036262524&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 14 | en_HK |
dc.identifier.issue | 3 | en_HK |
dc.identifier.spage | 325 | en_HK |
dc.identifier.epage | 330 | en_HK |
dc.identifier.isi | WOS:000175899000013 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Pak, CH=7402211440 | en_HK |
dc.identifier.scopusauthorid | Ng, EHY=35238184300 | en_HK |
dc.identifier.scopusauthorid | Oi, ST=7103241843 | en_HK |
dc.identifier.issnl | 1040-872X | - |